RAPP
Rapport Therapeutics, Inc. Common StockNASDAQHealthcare$33.58-3.57%ClosedMarket Cap: $1.23B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.14
P/S
0.00
EV/EBITDA
-9.43
DCF Value
$0.80
FCF Yield
-7.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-28.9%
ROA
-21.8%
ROIC
-25.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-38.5M | $-33.8M | $-0.72 | — |
| FY 2025 | $0.00 | -Infinity% | $-125.1M | $-111.5M | $-2.86 | — |
| Q3 2025 | $0.00 | NaN% | $-30.0M | $-26.9M | $-0.71 | — |
| Q2 2025 | $0.00 | NaN% | $-29.5M | $-26.7M | $-0.75 | — |
| Q1 2025 | $0.00 | NaN% | $-27.1M | $-24.1M | $-0.12 | — |
| Q4 2024 | $0.00 | NaN% | $-23.5M | $-20.0M | $-0.10 | — |
| FY 2024 | $0.00 | -Infinity% | $-83.1M | $-78.3M | $-0.38 | — |
| Q3 2024 | $0.00 | NaN% | $-21.6M | $-17.5M | $-0.09 | — |
| Q2 2024 | $0.00 | -Infinity% | $-20.8M | $-18.1M | $-0.09 | — |
| Q1 2024 | $0.00 | -Infinity% | $-17.1M | $-22.7M | $-0.12 | — |
| Q4 2023 | $0.00 | -Infinity% | $-14.8M | $-13.5M | $-0.07 | — |
| FY 2023 | $0.00 | -Infinity% | $-36.2M | $-34.8M | $-0.19 | — |